PLoS One
February 21, 2020
Bheatrix Bienemann, Nina Stamato Ruschel, Maria Luiza Pesse Campos et al.
81 citations
Psilocybin, found in psilocybe mushrooms, has low toxicity and addiction risk, but negative outcomes from its use are not well understood. Analyzing 346 self-reports from an online platform using textual analysis software, the study identified four main clusters: thinking distortions, emergencies, perceptual alterations, and substance administration. Bad trips were more frequent among female users and linked to thinking distortions. Using multiple doses in one session or combining psilocybin with other substances was associated with long-term negative outcomes, while single high doses of mushrooms were linked to medical emergencies. These findings can inform harm-reduction efforts.
Wiley Interdisciplinary Reviews Cognitive Science
December 3, 2023
Daniel C Mograbi, Simon Hall, Beatriz Arantes et al.
17 citations
Self-awareness, the capacity to regard oneself as an object of awareness, remains a puzzle addressed by religion, philosophy, and science. This review examines the neurocognitive mechanisms behind self-awareness, describing it as a multidimensional, emergent property that manifests at different levels of cognitive complexity, framed within predictive coding theory. It discusses how self-awareness is altered in neuropsychiatric conditions and evaluates alternative frameworks for understanding it in both health and psychopathology. The article identifies gaps in current knowledge and suggests directions for future research.
Current Neurology and Neuroscience Reports
August 1, 2024
Daniel C Mograbi, Rafael S. Rodrigues, Bheatrix Bienemann et al.
12 citations
Self-awareness—the capacity to make oneself the object of one's own attention—has clinical relevance, and understanding its neurochemical basis may clarify causes of and treatments for psychopathological conditions. This article reviews how psychedelics influence self-awareness by affecting brain networks such as the default-mode and salience networks, and neurotransmitters. Within a predictive-coding framework, it examines effects on interoception, body ownership, agency, metacognition, emotional regulation, and autobiographical memory. Improved emotional regulation and autobiographical memory have been observed with psychedelic use, suggesting changes in higher-order self-awareness, modulated by relaxed priors and enhanced cognitive flexibility. Bodily self-awareness alterations are less consistent, potentially varying with dose, acute versus long-term effects, and clinical conditions.
Journal of Psychoactive Drugs
August 19, 2022
Marcio S. C. Longo, Bheatrix Bienemann, Marco Multedo et al.
10 citations
People who currently use ayahuasca/DMT, psilocybe mushrooms, LSD, cannabis, or MDMA/ecstasy score higher on nature relatedness than those who have never used these substances. After accounting for sociodemographic factors, only current and past use of ayahuasca/DMT remained positively associated with nature relatedness. Among those who reported an intention to use psilocybe mushrooms in the future, that intention was also linked to higher nature relatedness. The findings suggest that classic serotonergic psychedelics may have a unique relationship with nature relatedness, but the cross-sectional design cannot establish causation.
Journal of Psychoactive Drugs
January 1, 2024
Julia M.k. Freind, Fernando R. Beserra, Bruno S Menezes et al.
9 citations
Depression is a widespread mental health disorder that causes severe emotional suffering and increases suicide risk. Ketamine and esketamine have expanded treatment options. A systematic review following PRISMA criteria analyzed existing protocols for treating depression with these substances. Results showed a predominance of medical approaches, with few studies on ketamine-assisted psychotherapy or other psychedelic-assisted therapies. Limited information was reported on psychosocial elements like preparation, psychological support during sessions, and integration of experiences. These findings suggest that treatment practices for depression with ketamine or esketamine diverge from those used with other psychedelic substances, highlighting directions for future research.
Journal of psychopharmacology (Oxford, England)
June 28, 2025
Rafael S. Rodrigues, Isabel Wießner, Dimitri Daldegan-Bueno et al.
6 citations
Two scales that measure altered states of consciousness—the OAV and the 5D-ASC—were adapted and validated for Brazilian Portuguese through expert review and back-translation. In an online survey of 3762 people recounting their psychedelic experiences, factor analyses confirmed an 11-factor structure for the OAV and a 6-factor structure for the 5D-ASC, both with strong internal consistency (α > 0.76). Convergent validity was supported by significant correlations with the Mystical Experience Questionnaire and Ego Dissolution Inventory. Factor scores differed by substance, setting, and meditation frequency; ayahuasca and DMT experiences produced higher oceanic boundlessness and anxious ego-dissolution scores. The scales show reliable psychometric properties for Brazil, though sample homogeneity and recall bias are limitations.
Trends in Psychiatry and Psychotherapy
October 18, 2022
Bheatrix Bienemann, Mariana Ridolfi, Marco Multedo et al.
5 citations
A validated scale for measuring ego dissolution demonstrated strong psychometric properties, though its factor structure may differ from the English version. Because validation is an ongoing process, further studies should compare ego dissolution scores across different substances and regions of the country.
Scientific Reports
November 10, 2023
Lucas Cruz, Bheatrix Bienemann, Fernanda Palhano-Fontes et al.
3 citations
Ayahuasca, a psychoactive brew used as an entheogen for centuries, is being investigated as a treatment for clinical disorders. This study analyzed open-ended descriptions from nine people with treatment-resistant depression and twenty healthy controls after their first ayahuasca experience. Using quantitative textual analysis, five clusters emerged: altered consciousness, cognitive changes, somatic alterations, auditory experiences, and visual content. People with depression reported more aversive bodily reactions. The findings align with known psychedelic experience patterns and may guide therapeutic use of ayahuasca.
Journal of Psychoactive Drugs
June 22, 2023
Bheatrix Bienemann, Amanda Rocha Barbosa, Lucas Villar Magalhães da Cruz et al.
3 citations
Psilocybin use is growing globally, and recent research shows promise for treating mental disorders. Analyzing 846 public online self-reports with textual analysis software, five clusters emerged describing mental experiences, cognitive processes, somatic experiences, perceptual alterations, and context of administration. The findings reinforce that psilocybin experiences commonly involve somatic and visual changes, feelings of connectedness and oneness with the world, the importance of setting, beneficial mystical experiences, and the phenomenon of ego dissolution. Understanding these circumstances may guide clinical use and harm reduction.
Journal of Clinical Psychology
June 15, 2026
Lucas Cruz, Fernando R. Beserra, Julia M.k. Freind et al.
Music is frequently used in psychedelic-assisted psychotherapy, but there is no standardized protocol for selecting or implementing it. A systematic review of 36 articles found that 25 mentioned music, mostly in studies of psilocybin and MDMA for depressive disorders and post-traumatic stress disorder. Procedures varied widely across studies, partly because different disorders and substances were investigated, and partly because no uniform guidelines exist. Identifying which features of music are prioritized may help guide future clinical practice and research.
Clinical Therapeutics
June 1, 2026
Anna Luiza Guimarães, Fernando R. Beserra, Lucas Cruz et al.
Interviews with 26 stakeholders in Brazil—including Indigenous leaders, clinicians, activists, and policymakers—revealed four barriers (accessibility, regulation, limited knowledge, and risks), three facilitators (need for innovation, scientific advancements, and legal loopholes), and four perspectives (integration of ancestral knowledge, idealization/mysticism/scientific rigor, user autonomy, and tangible social benefits) for psychedelic research and regulation. Themes were shared across groups but varied in emphasis, highlighting cultural, political, scientific, and clinical considerations for a region with a rich history of traditional psychedelic use.
Research Square
May 20, 2026
Isabel Wießner, Marcelo Falchi-Carvalho, Sophie Laborde et al.
The paper explores the relationships among DMT-induced experiences, psychosis, healing, mystical experiences, and positive emotionality. It examines how DMT can serve as a model for psychosis and as a therapeutic tool, while also considering the overlap between these models and mystical experiences. The authors discuss the potential for DMT to induce states resembling psychosis but also to facilitate healing and positive emotional outcomes, suggesting that the context and set and setting are crucial in determining whether the experience leads to distress or well-being.
Research Square (Research Square)
August 23, 2023
Lucas Villar Magalhães da Cruz, Bheatrix Bienemann Favero, Fernanda Palhano-Fontes et al.
First-time ayahuasca users with treatment-resistant depression and healthy controls described their subjective experiences in open-ended questions. Textual analysis of responses from nine depressed and 20 healthy individuals revealed five clusters: altered consciousness, cognitive changes, somatic alterations, auditory experiences, and visual perceptual content. Depressed participants reported more aversive bodily reactions, suggesting specific experiential features in depression. The results align with prior psychedelic research and may guide therapeutic applications of ayahuasca.
Consciousness and Cognition
September 1, 2020
Yury V M Lages, Daniel C Mograbi, Thomas E Krahe et al.
Understanding complex emotional states in animals reveals that 70% of researchers emphasize the importance of anthropomorphic perspectives, which help bridge human and animal emotions. By exploring different theories of consciousness and neural processing, insights into the subjective experiences of nonhuman animals expand. The debate between dualism and monism also shapes our understanding, while contrasting affective consciousness with higher-order emotional theories sheds light on how animals experience feelings uniquely. This nuanced view fosters a deeper appreciation for the emotional lives within diverse species.
Alzheimer's & dementia (New York, N. Y.)
January 1, 2021
Jonathan Huntley, Stephen M Fleming, Daniel C Mograbi et al.
People with Alzheimer's disease show a range of changes in consciousness, including reduced awareness of cognitive deficits, diminished self-awareness, and impaired introspection, which appear early and worsen as the disease progresses. These awareness impairments are linked to brain damage in areas that overlap with proposed neural correlates of consciousness. The authors argue that recognizing Alzheimer's disease as a disorder of consciousness is overdue and important for understanding patients' lived experience and improving care.